REG - GSK PLC - Director/PDMR Shareholding
17/02/2026 15:30
For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260217:nRSQ3805Ta&default-theme=true
RNS Number : 3805T GSK PLC 17 February 2026
GSK plc (the 'Company')
Vesting of Performance Share Plan Awards
This notification sets out the vesting details of awards over Ordinary Shares
and American Depositary Shares ('ADS') made to Persons Discharging Managerial
Responsibilities ('PDMRs') and their Persons Closely Associated ('PCAs') in
February 2023 under the GlaxoSmithKline 2017 Performance Share Plan ('PSP'),
which were subject to relevant business performance conditions, and the
subsequent sale of Ordinary Shares and ADS to meet tax liabilities. The
three-year performance period for these awards commenced on 1 January 2023 and
ended on 31 December 2025. The awards vested on 13 February 2026.
The performance measure outcomes and vesting levels for these awards are set
out in the following table.
Outcome and Vesting Level
Portion of the Award Measure and Outcome % of maximum % of award
30% Total Shareholder Return - For the three-year period the Company's Total 40% 12%
Shareholder Return ranked 5th, against a comparator group of 10 global
pharmaceutical companies including GSK.
20% Total Sales - For the three-year period, the Company achieved sales across our 100% 20%
marketed products for the measure of £99.03bn, which is above the level of
£94.58bn required for 100% vesting. The threshold vesting level was
£89.18bn.
20% Total Profit - For the three-year period, the Company achieved £30.22bn, 100% 20%
which is above the level of £29.43bn required for 100% vesting. The
threshold vesting level was £27.75bn.
20% Pipeline Progress - Measure is equally weighted between:
- Pivotal trial starts 100% 10%
- Major regulatory approvals 100% 10%
10% Responsible Business: Environment - For the three-year period, all criteria 100% 10%
for achieving our Trust priority and goal of having a Nature Net Positive and
Climate Net Zero impact by 2030 have been met or exceeded in advance of the
target date required to result in maximum vesting for this measure.
Total vesting for 2023 award 82% 82%
Lapsed 18%
The notifications that follow are for awards made to PDMRs and their PCAs and
detail the PSP conditional awards that vested, including dividends accrued
during the vesting period, on 13 February 2026. The balance of the award made
to each PDMR and PCA has lapsed.
The closing prices of Ordinary Shares and of ADS of GSK plc on the vesting
date were £21.65 and $58.93.
Transaction notification
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Luke Miels
b) Position/status Chief Executive Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary Shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The vesting of awards granted in 2023 under the Company's 2017 Performance
Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 245,716
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2026-02-13
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Luke Miels
b) Position/status Chief Executive Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities on the vesting of awards
granted in 2023 under the Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£21.6002 15,579
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2026-02-13
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Lynn Baxter
b) Position/status President, Europe
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary Shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The vesting of awards granted in 2023 under the Company's 2017 Performance
Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 10,908
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2026-02-13
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Lynn Baxter
b) Position/status President, Europe
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary Shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities on the vesting of awards
granted in 2023 under the Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£21.6002 4,240
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2026-02-13
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Diana Conrad
b) Position/status Chief People Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The vesting of awards granted in 2023 under the Company's 2017 Performance
Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 102,653
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2026-02-13
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Diana Conrad
b) Position/status Chief People Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities on the vesting of awards
granted in 2023 under the Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£21.6002 54,951
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2026-02-13
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mike Crichton
b) Position/status President, International
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary Shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The vesting of awards granted in 2023 under the Company's 2017 Performance
Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 10,908
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2026-02-13
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mike Crichton
b) Position/status President, International
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary Shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities on the vesting of awards
granted in 2023 under the Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£21.6002 4,255
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2026-02-13
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name James Ford
b) Position/status SVP and Group General Counsel, Legal and Compliance
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The vesting of awards granted in 2023 under the Company's 2017 Performance
Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 159,845
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2026-02-13
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name James Ford
b) Position/status SVP and Group General Counsel, Legal and Compliance
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities on the vesting of awards
granted in 2023 under the Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£21.6002 75,128
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2026-02-13
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Maya Martinez-Davis
b) Position/status President, US
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument American Depositary Shares ('ADS')
ISIN: US37733W2044
b) Nature of the transaction The vesting of awards granted in 2023 under the Company's 2017 Performance
Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
$0.00 42,631
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2026-02-13
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Maya Martinez-Davis
b) Position/status President, US
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument American Depositary Shares ('ADS')
ISIN: US37733W2044
b) Nature of the transaction The sale of ADS to meet tax liabilities on the vesting of awards granted in
2023 under the Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
$58.8509 15,630.222
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2026-02-13
f) Place of the transaction New York Stock Exchange (XNYS)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Nina Mojas
b) Position/status President, Global Product Strategy
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary Shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The vesting of awards granted in 2023 under the Company's 2017 Performance
Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 10,908
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2026-02-13
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Nina Mojas
b) Position/status President, Global Product Strategy
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary Shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities on the vesting of awards
granted in 2023 under the Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£21.6002 2,880
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2026-02-13
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Shobie Ramakrishnan
b) Position/status Chief Digital and Technology Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument American Depositary Shares ('ADS')
ISIN: US37733W2044
b) Nature of the transaction The vesting of awards granted in 2023 under the Company's 2017 Performance
Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
$0.00 59,379
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2026-02-13
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Shobie Ramakrishnan
b) Position/status Chief Digital and Technology Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument American Depositary Shares ('ADS')
ISIN: US37733W2044
b) Nature of the transaction The sale of ADS to meet tax liabilities on the vesting of awards granted in
2023 under the Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
$58.8509 30,806
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2026-02-13
f) Place of the transaction New York Stock Exchange (XNYS)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name David Redfern
b) Position/status President, Corporate Development
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The vesting of awards granted in 2023 under the Company's 2017 Performance
Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 171,300
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2026-02-13
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name David Redfern
b) Position/status President, Corporate Development
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities on the vesting of awards
granted in 2023 under the Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£21.6002 80,511
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2026-02-13
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Regis Simard
b) Position/status President, Global Supply Chain
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The vesting of awards granted in 2023 under the Company's 2017 Performance
Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 173,295
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2026-02-13
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Regis Simard
b) Position/status President, Global Supply Chain
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities on the vesting of awards
granted in 2023 under the Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£21.6002 81,449
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2026-02-13
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Phil Thomson
b) Position/status President, Global Affairs
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The vesting of awards granted in 2023 under the Company's 2017 Performance
Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 79,007
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2026-02-13
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Phil Thomson
b) Position/status President, Global Affairs
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities on the vesting of awards
granted in 2023 under the Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£21.6002 37,134
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2026-02-13
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Deborah Waterhouse
b) Position/status CEO, ViiV Healthcare and President, Global Health, GSK
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The vesting of awards granted in 2023 under the Company's 2017 Performance
Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 162,949
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2026-02-13
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Deborah Waterhouse
b) Position/status CEO, ViiV Healthcare and President, Global Health, GSK
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities on the vesting of awards
granted in 2023 under the Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£21.6002 76,587
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2026-02-13
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Tony Wood
b) Position/status Chief Scientific Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary Shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The vesting of awards granted in 2023 under the Company's 2017 Performance
Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 219,851
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2026-02-13
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Tony Wood
b) Position/status Chief Scientific Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary Shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities on the vesting of awards
granted in 2023 under the Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£21.6002 103,330
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2026-02-13
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Victoria Whyte
b) Position/status SVP & Company Secretary
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The vesting of awards granted in 2023 under the Company's 2017 Performance
Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 10,908
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2026-02-13
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Victoria Whyte
b) Position/status SVP & Company Secretary
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities on the vesting of awards
granted in 2023 under the Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£21.6002 5,127
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2026-02-13
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Neil Falkingham
b) Position/status PCA of Lynn Baxter (President, Europe)
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary Shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The vesting of awards granted in 2023 under the Company's 2017 Performance
Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£0.00 10,908
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2026-02-13
f) Place of the transaction N/A
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Neil Falkingham
b) Position/status PCA of Lynn Baxter (President, Europe)
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GSK plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary Shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
b) Nature of the transaction The sale of Ordinary Shares to meet tax liabilities on the vesting of awards
granted in 2023 under the Company's 2017 Performance Share Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£21.6002 5,259
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2026-02-13
f) Place of the transaction London Stock Exchange (XLON)
About GSK
GSK is a global biopharma company with a purpose to unite science, technology,
and talent to get ahead of disease together. Find out more at www.gsk.com
(http://www.gsk.com/) .
Registered in England & Wales:
No. 3888792
Registered Office:
79 New Oxford Street
London
WC1A 1DG
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHSFWFLWEMSELE
Copyright 2019 Regulatory News Service, all rights reservedRecent news on GSK
See all newsREG - GSK PLC - GSK completes acquisition of RAPT Therapeutics
AnnouncementREG - GSK PLC - Transaction in Own Shares
AnnouncementREG - GSK PLC - Total Voting Rights
AnnouncementREG - GSK PLC - Transaction in Own Shares
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
Announcement